Blinded sample size reestimation in multiarmed clinical trials

Drug Information Journal

Volumn 34, Issue 2, 2000, Pages 455-460

  Kieser, Meinhard ^a   Friede, Tim ^b  

^a DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Multiarmed clinical trials; Regulatory guidelines; Sample size estimation

Indexed keywords

CLINICAL RESEARCH; MATHEMATICAL MODEL; OUTCOMES RESEARCH; PERFORMANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SAMPLE; SAMPLING;

EID: 0034045125     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150003400214     Document Type: Review

References (22)

1. Stein C. A two-sample test for a linear hypothesis whose power is independent of the variance. Ann Math Stat. 1945;16:243-258.
2. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med. 1990;9:65-72.
3. Bristol D. Sample size determination using an interim analysis. J Biopharmaceutical Stat. 1993;3(2): 159-166.
4. Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Com Stat (A). 1992;21(10): 2833-2853.
5. Shih WJ. Sample size reestimation in clinical trials. Chapter 18. In Karl Peace ed. Biopharmaceutical Sequential Statistical Applications. New York: Marcel Dekker; 1992:285-301.
6. Shih WJ. Sample size reestimation for triple blind clinical trials. Drug Inf J. 1993;27(3):761-764.
7. Gould AL. Planning and revising the sample size for a trial. Stat Med. 1995;14:1039-1051.
8. Shih WJ, Gould AL. Re-evaluating design specifications of longitudinal clinical trials without unblinding when the key response is rate of change. Stat Med. 1995;14:2239-2248.
9. CPMP Working Party on Efficacy of Medicinal Products. Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. Stat Med. 1995;14:1659-1682.
10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: Statistical principles for clinical trials. Stat Med. 1999;18:1905-1942.
11. Birkett MA, Day S. Internal pilot studies for estimating sample size. Stat Med. 1994;13:2455-2463.
12. Sandvik L, Erikssen J, Mowinckel P, Rodland EA. A method for determining the size of internal pilot studies. Stat Med. 1996;15:1587-1590.
13. Gould AL. Issues in blinded sample size re-estimation. Com Stat (B). 1997;26(3):1229-1239.
14. Shih WJ, Long J. Blinded sample size re-estimation with unequal variances and center effects in clinical trials. Com Stat (A). 1998;27(2):395-408.
15. Singer J. Letter to the editor: A method for determining the size of internal pilot studies. Stat Med. 1999; 18:1151-1153.
16. Coffey CS, Muller KE. Exact test size and power of a gaussian error linear model for an internal pilot study. Stat Med. 1999;18:1199-1214.
17. Denne JS, Jennison C. Estimating the sample size for a t-test using an internal pilot. Stat Med. 1999; 18:1575-1585.
18. Wittes J, Schabenberger O, Zucker D, Brittain E, Proschan M. Internal pilot studies I: Type I error rate of the naive t-test. Stat Med. 1999;18:3481-3491.
19. Zucker DM, Wittes JT, Schabenberger O, Brittain E. Internal pilot studies II: Comparison of various procedures. Stat Med. 1999;18:3493-3509.
20. Kieser M, Friede T. Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Stat Med. In press.
21. Ruberg SJ. Dose response studies. II. Analysis and interpretation. J Biopharm Stat. 1995;5(1):15-42.
22. Schwertman NC. An alternative procedure for determining analysis of variance sample size. Com Stat (B). 1987;16(4):957-967.